Entera Bio (ENTX) announced that several members of its Board of Directors, including the Company’s Chairman, have made open market purchases of the Company’s ordinary shares. These transactions follow an earlier open market purchase by Entera Bio’s CEO Miranda Toledano, in December 2025. The purchases were made by Geno Germano, Chairman of the Board; Steven Rubin, Director; Haya Taitel, Director; and Sean Ellis, Director. The shares were acquired in open market transactions at prevailing market prices. Details regarding the transactions, including the number of shares purchased and the purchase prices, are reported in filings with the U.S. Securities and Exchange Commission.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENTX:
- Entera Bio Names Geno Germano Independent Board Chairman
- Entera Bio appoints Geno Germano as chairman of the board
- Entera Bio Expands OPKO Partnership, Adds New Director
- Opko Health Entera Bio, Entera Bio expand partnership to advance PTH tablet
- Entera Bio announces expected milestones for Q1 in 2026